Amgen Enbrel 50 Mg Syringe Expected To Simplify Dosing For Psoriasis
Executive Summary
Amgen expects to receive approval by year-end for an Enbrel 50 mg pre-filled syringe that could simplify dosing of the TNF inhibitor for treatment of plaque psoriasis and other indications
You may also be interested in...
Amgen Enbrel (correction)
Amgen did not run a statistical analysis on its clinical trial at six months (1"The Pink Sheet" May 17, 2004, p. 33). Enbrel (etanercept) received approval for psoriatic arthritis about a year before Biogen Idec Amevive (alefacept) gained approval for psoriasis...
Amgen Enbrel (correction)
Amgen did not run a statistical analysis on its clinical trial at six months (1"The Pink Sheet" May 17, 2004, p. 33). Enbrel (etanercept) received approval for psoriatic arthritis about a year before Biogen Idec Amevive (alefacept) gained approval for psoriasis...
Genentech Misses Enbrel Deadline; Amgen Contract Facility Not Ready
Genentech will not be reimbursed by Amgen for certain Enbrel manufacturing investments because Genentech's contract production line will not be ready on time, the company disclosed in its 2003 110-K filing